GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProKidney Corp (NAS:PROK) » Definitions » FCF Yield %

ProKidney (ProKidney) FCF Yield % : -69.18 (As of May. 11, 2024)


View and export this data going back to 2022. Start your Free Trial

What is ProKidney FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, ProKidney's Trailing 12-Month Free Cash Flow is $-124.27 Mil, and Market Cap is $179.62 Mil. Therefore, ProKidney's FCF Yield % for today is -69.18%.

The historical rank and industry rank for ProKidney's FCF Yield % or its related term are showing as below:

PROK' s FCF Yield % Range Over the Past 10 Years
Min: -150.78   Med: 0   Max: 0
Current: -69.18


PROK's FCF Yield % is ranked worse than
81.17% of 1556 companies
in the Biotechnology industry
Industry Median: -14.17 vs PROK: -69.18

ProKidney's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.


ProKidney FCF Yield % Historical Data

The historical data trend for ProKidney's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProKidney FCF Yield % Chart

ProKidney Annual Data
Trend Dec20 Dec21 Dec22 Dec23
FCF Yield %
- - -18.70 -116.59

ProKidney Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -15.22 -15.49 -10.80 -73.33 -101.16

Competitive Comparison of ProKidney's FCF Yield %

For the Biotechnology subindustry, ProKidney's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProKidney's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProKidney's FCF Yield % distribution charts can be found below:

* The bar in red indicates where ProKidney's FCF Yield % falls into.



ProKidney FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

ProKidney's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-124.266 / 106.586934
=-116.59%

ProKidney's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-26.956 * 4 / 106.586934
=-101.16%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ProKidney FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


ProKidney FCF Yield % Related Terms

Thank you for viewing the detailed overview of ProKidney's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


ProKidney (ProKidney) Business Description

Traded in Other Exchanges
Address
2000 Frontis Plaza Boulevard, Suite 250, Winston-Salem, NC, USA, 27103
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease.
Executives
Chamath Palihapitiya 10 percent owner THE SOCIAL-CAPITAL PARTNERSHIP, L.L.C., 506 SANTA CRUZ AVENUE, SUITE 300, MENLO PARK CA 94025
Sc Pipe Holdings Llc 10 percent owner 506 SANTA CRUZ AVE., SUITE 300, MENLO PARK CA 94025
Sc Master Holdings, Llc 10 percent owner 506 SANTA CRUZ AVENUE, SUITE 300, MENLO PARK CA 94025
Bruce Culleton officer: EVP, Clinical Development 2000 FRONTIS PLAZA BLVD., SUITE 250, WINSTON-SALEM NC 27103
Aaron Cowen 10 percent owner 540 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Mary Weger officer: Chief People Officer ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142
William F Doyle director
Tolerantia, Llc 10 percent owner 110 EAST 59TH STREET, SUITE 3300, NEW YORK NY 10022
Jimenez Santos Jose Ignacio director C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103
Deepak Jain officer: Chief Operating Officer C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103
Darin J. Weber officer: SVP of Regulatory Development C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103
Libbie Parker Mckenzie officer: Chief Medical Officer C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103
James Coulston officer: Chief Financial Officer C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103
Jennifer A. Fox director C/O NUVATION BIO INC., 1500 BROADWAY, SUITE 1401, NEW YORK NY 10036
Timothy Bertram director, officer: Chief Executive Officer C/O TENGION, INC., 2900 POTSHOP LANE, SUITE 100, EAST NORRITON PA 19403